ArticleFrontiers in physiology2025
Clinical, electromyographic, and biophysical characterization of the rare Nav1.4 channel mutation
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Our aims were to provide an integrated clinical and biophysical characterization of the rare variant NM_000334.4(SCN4A) c.4307T>C (p.Leu1436Pro; L1436P), affecting the skeletal muscle sodium channel Nav1.4, and to compare its functional consequences with both wild-type (WT) channels and the well-established pathogenic variant p.Arg1448His (R1448H). Methods: We retrospectively analyzed nine unrelated patients carrying the heterozygous L1436P variant. Clinical evaluation included neurological examination and standardized electrodiagnostic protocols. Electromyographic studies were performed at baseline and after muscle cooling. In addition, the biophysical characteristics of the mutant channels were compared to those of WT channels and R1448H, using whole-cell patch clamp recordings of hNav1.4 currents in stably transfected HEK293 cells. Recordings were performed at near physiological temperature (32°C), room temperature (22°C) and cold temperature (15°C). Results: The clinical phenotypes associated with this SCN4A mutation included sodium channel myotonia (SCM) (case 1), paramyotonia congenita (cases 2, 3, 4, 5, 7 and 8), and cold-aggravated myotonia (case 6) (case 6). Regarding the phenotype of hyperkalemic periodic paralysis, three probands described episodes of muscle weakness (cases 2, 4 and 9). Whole-cell recordings allowed to pinpoint the biophysical defects of L1436P. Thus, this mutation induced a significant slowing down of fast inactivation of the Nav current at several voltages, but this effect was less marked than in R1448H. The L1436P mutation also tended to induce a right shift in the steady-state inactivation curve, but only at cold temperature. On the other hand, a leftward shift in the activation curve was seen at cold and room temperatures with R1448H, but not L1436P. Recovery from fast inactivation was slowed down in both mutants, but only at cold temperature. Discussion: Our study confirms that the SCN4A-L1436P mutation can give rise to a spectrum of clinical presentations. Epigenetic alterations, modifying genes or environmental factors may influence clinical expression. Our experimental data indicates a relatively milder biophysical phenotype for L1436P as compared to R1448H, which becomes more pronounced at lower temperatures, consistent with the clinical phenotype of a majority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.